MedTrace Logo

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

NCT00301756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-08-20

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant potential tumors. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Fallopian Tube Carcinoma
  • Primary Peritoneal Carcinoma
  • Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor
  • Recurrent Ovarian Carcinoma
  • Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor
  • Stage III Ovarian Cancer
  • Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor
  • Stage IV Ovarian Cancer

Interventions

DRUG

Belinostat

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Amit Oza · University Health Network Princess Margaret Cancer Center P2C

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-08-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00301756 on ClinicalTrials.gov